ClinicalTrials.gg
Not yet recruitingNCT07111442FAIRUpdated Aug 8, 2025

A Placebo-controlled Trial of Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Among Atherosclerosis Renal-vascular Hypertension Patients

An interventional study of renal artery fractional flow reserve measurement and dopamine in Renal Artery Stenosis Atherosclerotic and Secondary Hypertension Renal Arterial, sponsored by Peking University First Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-08.

Sponsored by Peking University First Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
171st of 308
200 · median 253
Started
2025
with 47 others
No phase
146 of 410
56 open now
Primary completion
2028-08
later than 121 of 147 live
Registered
344th of 410
by date
Lead sponsor
7 of 410
Peking University First Hospital

Among the 410 studies in Hypertension with a site in China, this one is the 171st largest by planned enrollment of the 308 interventional ones that give a count, is one of 48 that started in 2025, is one of 146 with no phase, reaches primary completion later than 121 of the 147 other live ones, and was the 344th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 124 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 410 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

Objective: To determine whether percutaneous renal artery stenting guided by fractional flow reserve (FFR), in addition to standard medical therapy, provides superior therapeutic efficacy compared to medical therapy alone in patients with atherosclerotic renal artery stenosis and hypertension.

Study Design: A double-blind, multicenter, prospective, randomized, placebo-controlled (sham procedure) trial.

Primary Endpoint: The percentage reduction in daytime mean systolic blood pressure measured by ambulatory blood pressure monitoring (ABPM) from baseline to 3 months after the procedure.

Study Population: A total of 200 patients who are potential candidates for renal artery intervention will be enrolled. Participants must meet all of the following inclusion criteria to be eligible for the study.

Participant Screening and Enrollment: Once a patient is preliminarily assessed in the outpatient clinic and meets the clinical inclusion/exclusion criteria, written informed consent will be obtained, and the patient will enter a 1-week screening period. During this period, patients will perform home blood pressure monitoring using a calibrated Bluetooth-enabled device provided by the study team, which automatically uploads data. In addition, antihypertensive medications will be standardized to optimize blood pressure management.

If home BP measurements during the screening period continue to meet inclusion criteria, baseline ABPM will be conducted.

Following standardized renal angiography, patients whose renal anatomy meets the angiographic inclusion/exclusion criteria will undergo functional assessment of the stenotic lesion using a pressure wire and measurement of renal fractional flow reserve (FFR) under dopamine-induced maximal hyperemia, in accordance with the Standard Operating Procedure (SOP).

Patients who qualify will then be randomized based on FFR results using an Interactive Response Technology (IRT) system. All eligible patients will be assigned a unique subject identification number during screening, and randomization will occur on the day of angiography, ensuring allocation concealment and unbiased group assignment.

Study Intervention: Eligible participants who meet all inclusion and exclusion criteria will undergo renal angiography. On the day of angiography, a functional assessment of renal artery stenosis will be performed according to the Standard Operating Procedure (SOP) using a pressure wire under dopamine-induced maximal hyperemia to measure the Fractional Flow Reserve (FFR).

  • If FFR ≥ 0.80, no renal artery stenting will be performed.
  • If FFR \< 0.80, participants will be randomized in a 1:1 ratio to one of the following two intervention arms:

    • Stenting Group: Renal artery stenting
    • Control Group: Sham procedure The randomization assignment will be blinded to participants and follow-up investigators. Only designated study investigators and the operating team will be aware of the group allocation. For participants randomized to the sham procedure, the procedure will last at least 15 minutes to simulate actual intervention according to SOP guidelines. Group allocation will remain blinded until the primary endpoint is assessed at 3 months post-procedure.

All participants, regardless of group assignment, will receive guideline-directed optimized medical therapy throughout the study period.

Study Duration and Follow-up: Participants will be followed for a total of 12 months with study visits scheduled at the following time points:

  • 4 weeks post-procedure (telephone visit)
  • 12 weeks (clinic visit)
  • 6 months (clinic visit)
  • 12 months (clinic visit)

To minimize the impact of antihypertensive medication adjustments on statistical outcomes, it is strongly recommended that no changes be made to antihypertensive regimens during the first 3 months after enrollment unless clinically necessary, such as in cases of:

  • Systolic BP \< 100 mmHg, or
  • Systolic BP > 180 mmHg and/or diastolic BP > 100 mmHg. All changes to antihypertensive therapy (including drug type and dosage) will be documented in detail.

To ensure consistency and quality, standardized recommendations for antihypertensive drug selection and adjustment will be provided in accordance with current hypertension management guidelines.

03

Conditions studied

  • Renal Artery Stenosis Atherosclerotic
  • Secondary Hypertension Renal Arterial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 18 years or older.
  2. Documented history of hypertension and currently taking two or more antihypertensive medications with uncontrolled blood pressure (defined as daytime systolic BP ≥135 mmHg and/or diastolic BP ≥85 mmHg on optimized medication therapy, as measured by baseline ABPM).
  3. Clinical evidence suggestive of renal artery stenosis, and scheduled for renal angiography.
  4. Willing and able to provide written prior to initiation of any study-related procedures, and willing to comply with all study requirements.
  5. Renal angiography shows ≥70% to \<99% stenosis in at least one main renal artery with a reference vessel diameter of ≥4.0 mm.

Exclusion criteria

Exclusion Criteria:

  1. Systolic BP ≥200 mmHg and/or diastolic BP ≥120 mmHg on the day of randomization.
  2. Suspected non-atherosclerotic causes of RAS, such as fibromuscular dysplasia or large-vessel vasculitis.
  3. Pregnant or breastfeeding women.
  4. Participation in another clinical trial that, in the investigator's opinion, could interfere with this study.
  5. Stroke or within 3 months and known ≥70% carotid artery stenosis.
  6. Major surgery, myocardial infarction, or any interventional procedure within the past 30 days.
  7. Known \<30%.
  8. ≤1 year.
  9. Known allergy to contrast media or to any of the following medications: aspirin, clopidogrel.
  10. History of renal transplantation.
  11. Prior renal artery stenting or bypass surgery.
  12. Affected kidney length \<8 cm on Doppler ultrasound.
  13. Serum creatinine >3.0 mg/dL (265.2 μmol/L) at baseline visit (measured by local laboratory).
  14. Reference vessel diameter \<4 mm or >8 mm on angiography.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Other
    Registry group

    If FFR ≥ 0.80, no renal artery stenting will be performed.

    Diagnostic Test: renal artery fractional flow reserve measurement · Drug: dopamine

  • Experimental
    Stenting group

    If FFR \< 0.80, participants will be randomized in a 1:1 ratio to one of the following two intervention arms: Stenting Group: Renal artery tenting

    Diagnostic Test: renal artery fractional flow reserve measurement · Drug: dopamine · Device: renal artery stent

  • Sham comparator
    Control Group

    If FFR \< 0.80, participants will be randomized in a 1:1 ratio to one of the following two intervention arms: Control Group: Sham procedure

    Diagnostic Test: renal artery fractional flow reserve measurement · Drug: dopamine · Other: sham stenting

Interventions

  • Diagnostic testrenal artery fractional flow reserve measurement

    Eligible participants who meet all inclusion and exclusion criteria will undergo renal angiography. On the day of angiography, a functional assessment of renal artery stenosis will be performed according to the Standard Operating Procedure (SOP) using a pressure wire under dopamine-induced maximal hyperemia to measure the Fractional Flow Reserve (FFR).

  • Administer dopamine at 50 µg/kg via the renal artery to induce hyperemic.

  • Devicerenal artery stent

    Stent will be treated for the stenotic renal artery for patients randomized to stenting group

  • Othersham stenting

    For participants randomized to the sham procedure, the procedure will last at least 15 minutes to simulate actual intervention according to SOP guidelines.

06

What researchers measure

Primary outcomes

  1. The percentage reduction in daytime mean systolic blood pressure measured by ambulatory blood pressure monitoring from baseline to 3 months post-procedure.

    Time frame: from baseline to three months after procedure

Secondary outcomes

  1. Percentage change in the composite index of antihypertensive medication use

    Time frame: from baseline to 3 months post-procedure

  2. Percentage reduction in 24-hour/daytime/nighttime mean systolic blood pressure measured by ambulatory blood pressure monitoring

    Time frame: from baseline to 3 months post-procedure

  3. Percentage reduction in systolic blood pressure measured by home blood pressure monitoring

    Time frame: from baseline to 3 months post-procedure

  4. Percentage reduction in office systolic blood pressure

    Time frame: from baseline to 3 months post-procedure

  5. Change in the number of antihypertensive medications

    Time frame: from baseline to 3 months post-procedure

  6. Number of hypertensive emergencies

    Time frame: from baseline to 3 months post-procedure

  7. Percentage reduction in daytime mean systolic blood pressure by ambulatory blood pressure monitoring

    Time frame: from baseline to 6 months post-procedure

  8. Percentage reduction in daytime mean systolic blood pressure by ambulatory blood pressure monitoring

    Time frame: from baseline to 12 months post-procedure

Other outcomes

  1. All-cause mortality

    Time frame: 1 year post-procedure

  2. Cardiovascular death

    Time frame: 1 year post-procedure

  3. Acute myocardial infarction

    Time frame: 1 year post-procedure

  4. Non-fatal stroke

    Time frame: 1 year post-procedure

  5. Rehospitalization for congestive heart failure

    Time frame: 1 year post-procedure

  6. Progression of renal insufficiency (change in eGFR) or need for dialysis

    Time frame: 1 year post-procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Aug 2028, 36 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 36 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Aug 8, 2025
StartEst.
Aug 30, 2025
Primary completionEst.
Aug 30, 2028
CompletionEst.
Aug 30, 2029
Last update
Aug 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07111442
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Aug 30, 2025 (estimated)
Primary completion
Aug 30, 2028 (estimated)
Completion
Aug 30, 2029 (estimated)
Last update
Aug 8, 2025

Study contacts

Yuxi Li, MD
Contact
liyuxi@bjmu.edu.cn
00861083572283

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion